Based on the testing we have as patients, do we already have the information on our testing results that would tell us if we have the markers making us more likely to achieve a treatment free remission versus markers that lessen the possibility of a TFR?
The testing is a type of specialized Flow Cytometry (FC). Previous FC testing would not be useful. The point is whether the patient has very low MPL at the current time, not at some time in the past.
The papers do not address the question you asked. They are simply saying that if enhanced MPL signalling is detected it means those cells are probably high level leukemic stem cells. They also imply MPL might be a target for inhibition, but more research would be needed.
The real value of the enhanced MPL testing in my view would be to detect very low levels of residual disease, far below what a PCR or even DNA PCR could detect. So this could be used to determine if disease levels are nearer to absolute zero than PCRU implies. In that sense, I suppose the test for enhanced MPL (done using a type of Flow Cytometry) could show if someone is far below PCRU vs barely PCRU. And if that shows who is more likely to achieve TFR during cessation, that testing could be useful. But it is unknown whether levels of MPL are useful for prediction of TFR.
Edited by Trey, 13 March 2016 - 04:32 PM.